Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year High – Still a Buy?

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) reached a new 52-week high during trading on Tuesday . The company traded as high as $30.16 and last traded at $30.2570, with a volume of 1782692 shares traded. The stock had previously closed at $29.53.

Analyst Upgrades and Downgrades

ROIV has been the subject of several recent analyst reports. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Weiss Ratings downgraded Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 9th. Guggenheim increased their price target on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Finally, Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Roivant Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $28.81.

Roivant Sciences Price Performance

The company has a fifty day simple moving average of $24.72 and a 200-day simple moving average of $20.28. The company has a market cap of $21.45 billion, a P/E ratio of -25.64 and a beta of 1.17.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Matthew Gline sold 1,740,000 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $21.68, for a total transaction of $37,723,200.00. Following the completion of the sale, the chief executive officer directly owned 17,290,820 shares of the company’s stock, valued at approximately $374,864,977.60. This represents a 9.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mayukh Sukhatme sold 1,018,995 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the completion of the transaction, the insider owned 20,267,429 shares of the company’s stock, valued at approximately $440,005,883.59. The trade was a 4.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 13,118,014 shares of company stock worth $311,557,023. Corporate insiders own 10.80% of the company’s stock.

Institutional Trading of Roivant Sciences

Several large investors have recently added to or reduced their stakes in ROIV. Pacer Advisors Inc. lifted its holdings in shares of Roivant Sciences by 24.0% in the fourth quarter. Pacer Advisors Inc. now owns 70,259 shares of the company’s stock valued at $1,525,000 after purchasing an additional 13,609 shares in the last quarter. Dorsey Wright & Associates purchased a new stake in Roivant Sciences in the 4th quarter worth about $8,162,000. Invesco Ltd. boosted its position in Roivant Sciences by 28.9% during the 4th quarter. Invesco Ltd. now owns 2,281,487 shares of the company’s stock worth $49,508,000 after acquiring an additional 512,129 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in Roivant Sciences during the 4th quarter valued at about $227,000. Finally, Empowered Funds LLC purchased a new stake in shares of Roivant Sciences in the fourth quarter worth approximately $396,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.